The enrollment criteria for the VALID is different from those of other major post-MI ACE inhibitor trials in that patients with milder systolic LV dysfunction (EF <50%) is eligible for VALID while more severe form of LV dysfunction (EF <35% or clinical sign of heart failure) was required for enrollment in previous major clinical trials [9-12]. Here, ACE is linked to heart failure.